Incyte Corporation
NASDAQIncyte Corporation delivered a Q2 beat strong enough to flip the narrative — the defensive positioning that dominated the pre-earnings setup has given way to a swift repricing, with the stock up 9.3% on Tuesday and 10.7% on the week to close at $129.93. The most telling development after the print is the speed of analyst target revisions. Five firms raised targets on Wednesday…
Snapshot as of 6 Aug 2026
Incyte Corporation delivered a Q2 beat strong enough to flip the narrative — the defensive positioning that dominated the pre-earnings setup has given way to a swift repricing, with the stock up 9.3% on Tuesday and…
Incyte Corporation reports Q2 results today against a backdrop of rising put demand, cluster insider selling, and a broadly cautious analyst setup that leaves the stock trading above the Street's mean target. Options…
Incyte enters the final stretch before its July 28 earnings with a striking split in positioning signals: options traders have turned sharply more bullish while short sellers have spent the past month rebuilding their…
Incyte Corporation heads into the final stretch before its July 28 Q2 print with an unusual split in signals — short sellers are covering at the fastest pace in months, yet options traders are hedging more than they…
Incyte Corporation reported Q1 2026 results on April 28, and the market reacted better than bears expected — yet short sellers are still adding to positions, and options traders are hedging at an intensity not seen in…
Incyte Corporation trades at $96.74, up 6.6% over the past month despite a modest 0.4% dip this week. The biotech firm reports Q1 2026 results on April 28. Short interest sits at 5.79% of float. That's low for biotech.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INCY — free to start on ORTEX.
Sign up for free →Open INCY on ORTEX